Avorn, Jerry

Variable Selection for Propensity Score Models

Brookhart, M. A., Schneeweiss, S., Rothman, K. J., Glynn, R. J., Avorn, J., & Stürmer, T. (2006) · American Journal of Epidemiology

Advanced Causal Inference TechniquesStatistical Methods in Epidemiology

Cited by 2,336

High-dimensional propensity score adjustment in studies of treatment effects using health care claims data.

Schneeweiss, S., Rassen, J. A., Glynn, R. J., Avorn, J., Mogun, H., & Brookhart, M. A. (2009) · Epidemiology

Advanced Causal Inference TechniquesStatistical Methods in Epidemiology

Cited by 1,128

A combined comorbidity score predicted mortality in elderly patients better than existing scores

Gagne, J. J., Glynn, R. J., Avorn, J., Levin, R., & Schneeweiss, S. (2011) · Journal of Clinical Epidemiology

Chronic Disease Management StrategiesFrailty in Older Adults

Cited by 995

Risk of Death in Elderly Users of Conventional vs. Atypical Antipsychotic Medications

Wang, P. S., Schneeweiss, S., Avorn, J., Fischer, M. A., Mogun, H., Solomon, D. H., & Brookhart, M. A. (2005) · New England Journal of Medicine

Schizophrenia research and treatmentPharmaceutical Practices and Patient Outcomes

Cited by 959

Self-management Education Programs in Chronic Disease: A Systematic Review and Methodological Critique of the Literature

Warsi, A., Wang, P. S., LaValley, M. P., Avorn, J., & Solomon, D. H. (2004) · Archives of Internal Medicine

Chronic Disease Management StrategiesDiabetes Management and Education

Cited by 732

Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer

Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology

Medication Adherence and ComplianceBreast Cancer Treatment Studies

Cited by 676

The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform

Kesselheim, A. S., Avorn, J., & Sarpatwari, A. (2016) · JAMA

Pharmaceutical Economics and PolicyHealthcare Policy and Management

Cited by 592

Telephone Screening, Outreach, and Care Management for Depressed Workers and Impact on Clinical and Work Productivity Outcomes: A Randomized Controlled Trial

Wang, P. S., Simon, G. E., Avorn, J., Azocar, F., Ludman, E. J., McCulloch, J., Petukhova, M. Z., & Kessler, R. C. (2007) · JAMA

Workplace Health and Well-beingMental Health Treatment and Access

Cited by 408

A randomized trial of a program to reduce the use of psychoactive drugs in nursing homes

Avorn, J., Soumerai, S. B., Everitt, D. E., Ross-Degnan, D., Beers, M. H., Sherman, D., Salem-Schatz, S. R., & Fields, D. (1992) · New England Journal of Medicine

Pharmaceutical Practices and Patient OutcomesGeriatric Care and Nursing Homes

Cited by 397

Hazardous Benzodiazepine Regimens in the Elderly: Effects of Half-Life, Dosage, and Duration on Risk of Hip Fracture

Wang, P. S., Bohn, R. L., Glynn, R. J., Mogun, H., & Avorn, J. (2001) · American Journal of Psychiatry

Pharmaceutical Practices and Patient OutcomesBalance, Gait, and Falls Prevention

Cited by 312

Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study

Kim, D. H., Glynn, R. J., Avorn, J., Lipsitz, L. A., Rockwood, K., Pawar, A., & Schneeweiss, S. (2019) · The Journals of Gerontology: Series A

Frailty in Older AdultsChronic Disease Management Strategies

Cited by 285

Statins and congenital malformations: cohort study

Bateman, B. T., Hernandez-Diaz, S., Fischer, M. A., Seely, E. W., Ecker, J. L., Franklin, J. M., Desai, R. J., Allen-Coleman, C., Mogun, H., Avorn, J., et al. (2015) · BMJ

Pregnancy and Medication ImpactPharmacological Effects and Toxicity Studies

Cited by 236

Differences in Adverse Effect Reporting in Placebo Groups in SSRI and Tricyclic Antidepressant Trials: A Systematic Review and Meta-Analysis

Rief, W., Nestoriuc, Y., von Lilienfeld-Toal, A., Dogan, I., Schreiber, F., Hofmann, S. G., Barsky, A. J., & Avorn, J. (2009) · Drug Safety

Meta-analysis and systematic reviewsPharmaceutical industry and healthcare

Cited by 202

Dopamine Antagonists and the Development of Breast Cancer

Wang, P. S., Walker, A. M., Tsuang, M. T., Orav, E. J., Glynn, R. J., Levin, R., & Avorn, J. (2002) · Archives of General Psychiatry

Schizophrenia research and treatmentCancer Risks and Factors

Cited by 196

A Randomized Study of How Physicians Interpret Research Funding Disclosures

Kesselheim, A. S., Robertson, C. T., Myers, J. A., Rose, S. L., Gillet, V., Ross, K. M., Glynn, R. J., Joffe, S., & Avorn, J. (2012) · New England Journal of Medicine

Pharmaceutical industry and healthcareEthics in Clinical Research

Cited by 183

Medication-Attributed Adverse Effects in Placebo Groups: Implications for Assessment of Adverse Effects

Rief, W., Avorn, J., & Barsky, A. J. (2006) · Archives of Internal Medicine

Statistical Methods in Clinical TrialsPain Management and Placebo Effect

Cited by 167

National trends in antidepressant medication treatment among publicly insured pregnant women

Huybrechts, K. F., Palmsten, K., Mogun, H., Kowal, M., Avorn, J., Setoguchi-Iwata, S., & Hernández-Díaz, S. (2013) · General Hospital Psychiatry

Pregnancy and Medication ImpactMaternal Mental Health During Pregnancy and Postpartum

Cited by 161

Comparative Effectiveness of Generic and Brand-Name Statins on Patient Outcomes: A Cohort Study

Gagne, J. J., Choudhry, N. K., Kesselheim, A. S., Polinski, J. M., Hutchins, D., Matlin, O. S., Brennan, T. A., Avorn, J., & Shrank, W. H. (2014) · Annals of Internal Medicine

Lipoproteins and Cardiovascular HealthMedication Adherence and Compliance

Cited by 155

New “21st Century Cures” Legislation: Speed and Ease vs Science

Kesselheim, A. S., & Avorn, J. (2017) · JAMA

Pharmaceutical Economics and PolicyBiomedical Ethics and Regulation

Cited by 93

Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers

Glynn, R. J., Brookhart, M. A., Stedman, M., Avorn, J., & Solomon, D. H. (2007) · Medical Care

Statistical Methods in Clinical TrialsHealth Policy Implementation Science

Cited by 72

The Failure of Solanezumab — How the FDA Saved Taxpayers Billions

Sacks, C. A., Avorn, J., & Kesselheim, A. S. (2017) · New England Journal of Medicine

Biomedical Ethics and RegulationPharmaceutical Economics and Policy

Cited by 55

Osteoporosis action: design of the healthy bones project trial

Solomon, D. H., Brookhart, M. A., Polinski, J., Katz, J. N., Cabral, D., Licari, A., & Avorn, J. (2005) · Contemporary Clinical Trials

Bone health and osteoporosis researchPharmaceutical Practices and Patient Outcomes

Cited by 16

Which patients with unstable angina or non-Q-wave myocardial infarction should have immediate cardiac catheterization? A clinical decision rule for predicting who will fail medical therapy

Solomon, D. H., Ganz, D. A., Avorn, J., Glynn, R. J., Knight, E. L., Gibson, C. M., & Stone, P. H. (2002) · Journal of Clinical Epidemiology

Acute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

Cited by 15

Variations in Use of Diabetes Drugs With Cardiovascular Benefits Among Medicaid Patients

Zhai, M. Z., Avorn, J., Liu, J., & Kesselheim, A. S. (2022) · JAMA Network Open

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 7